Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism | Zendy

Tamara Vokes | Zendy; Michael Mannstadt | Zendy; Michael A. Levine | Zendy; B.L. Clarke | Zendy; Péter Lakatos | Zendy; Kristina Chen | Zendy; Rebecca Piccolo | Zendy; Alan Krasner | Zendy; Dolores Shoback | Zendy; John P. Bilezikian | Zendy

Open Access

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism

Author(s) -

Tamara Vokes,

Michael Mannstadt,

Michael A. Levine,

B.L. Clarke,

Péter Lakatos,

Kristina Chen,

Rebecca Piccolo,

Alan Krasner,

Dolores Shoback,

John P. Bilezikian

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-01471

Subject(s) - medicine , parathyroid hormone , placebo , hypoparathyroidism , vitamin d and neurology , endocrinology , randomization , hormone , calcium , quality of life (healthcare) , vitamin , randomized controlled trial , alternative medicine , nursing , pathology

Reduced health-related quality of life (HRQoL) is common in patients with hypoparathyroidism treated conventionally with calcium and active vitamin D supplements.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research